New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
December 7, 2012
07:26 EDTAMRNAmarin allowed key ANCHOR '520 patent, says Jefferies
Jefferies said it learned that the U.S. patent office allowed the key ANCHOR '520 patent, which is views as a major positive for Amarin. Further, Jefferies firm thinks Amarinís non-dilutive debt financing and decision to hire a salesforce to launch Vascepa in Q1 should have been expected given the lack of clarity around FDA exclusivity. Jefferies keeps a Buy rating on the stock with a $28 price target.
News For AMRN From The Last 14 Days
Check below for free stories on AMRN the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
There are no results for AMRN

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use